CN1240382C - 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 - Google Patents

以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 Download PDF

Info

Publication number
CN1240382C
CN1240382C CNB028088980A CN02808898A CN1240382C CN 1240382 C CN1240382 C CN 1240382C CN B028088980 A CNB028088980 A CN B028088980A CN 02808898 A CN02808898 A CN 02808898A CN 1240382 C CN1240382 C CN 1240382C
Authority
CN
China
Prior art keywords
methyl
hydrogen atom
ethyl
formula
represent hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028088980A
Other languages
English (en)
Chinese (zh)
Other versions
CN1505510A (zh
Inventor
B·布里
P·卡塞拉斯
J·－M·德罗克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1505510A publication Critical patent/CN1505510A/zh
Application granted granted Critical
Publication of CN1240382C publication Critical patent/CN1240382C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028088980A 2001-04-27 2002-04-26 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 Expired - Fee Related CN1240382C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/05843 2001-04-27
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (2)

Publication Number Publication Date
CN1505510A CN1505510A (zh) 2004-06-16
CN1240382C true CN1240382C (zh) 2006-02-08

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028088980A Expired - Fee Related CN1240382C (zh) 2001-04-27 2002-04-26 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合
CNA028089596A Pending CN1505511A (zh) 2001-04-27 2002-04-26 吡啶并吲哚酮类衍生物用于制备药物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028089596A Pending CN1505511A (zh) 2001-04-27 2002-04-26 吡啶并吲哚酮类衍生物用于制备药物的用途

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1240382C (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108261A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2444334A1 (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ295224B6 (enExample)
DE (2) DE60208365T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US6967203B2 (en) 2005-11-22
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
CA2443012A1 (en) 2002-11-07
RS50791B (sr) 2010-08-31
ES2254683T3 (es) 2006-06-16
CZ295224B6 (cs) 2005-06-15
EE200300465A (et) 2003-12-15
EP1385512B1 (fr) 2005-12-28
ES2271264T3 (es) 2007-04-16
ATE314070T1 (de) 2006-01-15
HK1059895A1 (en) 2004-07-23
CZ20032910A3 (en) 2004-07-14
WO2002087574A3 (fr) 2003-02-13
IL158312A0 (en) 2004-05-12
BG108260A (bg) 2004-12-30
BR0209138A (pt) 2004-06-08
DE60214533D1 (de) 2006-10-19
SK13242003A3 (sk) 2004-03-02
IL158266A (en) 2009-09-01
DK1385513T3 (da) 2007-01-15
UA74876C2 (en) 2006-02-15
KR20040015138A (ko) 2004-02-18
HK1060066A1 (en) 2004-07-30
US7160895B2 (en) 2007-01-09
YU83403A (sh) 2006-08-17
CN1505511A (zh) 2004-06-16
RU2292888C2 (ru) 2007-02-10
JP2004531538A (ja) 2004-10-14
CZ299465B6 (cs) 2008-08-06
CN1505510A (zh) 2004-06-16
EP1385513A1 (fr) 2004-02-04
CZ20032909A3 (en) 2004-06-16
EA005930B1 (ru) 2005-08-25
ZA200307785B (en) 2004-10-06
MXPA03009639A (es) 2004-06-30
IS2441B (is) 2008-11-15
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
NZ528671A (en) 2004-06-25
PL366910A1 (en) 2005-02-07
SK13252003A3 (sk) 2004-03-02
CA2444334A1 (fr) 2002-11-07
US20050272760A1 (en) 2005-12-08
IS6984A (is) 2003-10-09
PL366916A1 (en) 2005-02-07
HUP0400745A2 (hu) 2004-08-30
CA2443012C (fr) 2009-07-28
HUP0400744A2 (hu) 2004-06-28
CY1105813T1 (el) 2011-02-02
WO2002087575A1 (fr) 2002-11-07
RS50790B (sr) 2010-08-31
KR100847413B1 (ko) 2008-07-18
EA200301062A1 (ru) 2004-04-29
US20040122027A1 (en) 2004-06-24
DE60208365T2 (de) 2006-09-07
JP2004528343A (ja) 2004-09-16
FR2823975A1 (fr) 2002-10-31
YU83903A (sh) 2006-08-17
PT1385512E (pt) 2006-05-31
DK1385512T3 (da) 2006-05-22
US7524857B2 (en) 2009-04-28
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
PT1385513E (pt) 2007-01-31
NO20034787L (no) 2003-12-23
EP1385513B1 (fr) 2006-09-06
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
NO20034787D0 (no) 2003-10-24
AR034313A1 (es) 2004-02-18
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
US20040122036A1 (en) 2004-06-24
DE60214533T2 (de) 2007-06-21
IL158312A (en) 2009-09-01
EE200300466A (et) 2003-12-15
NO20034785D0 (no) 2003-10-24
RU2003130376A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
DK2979700T3 (en) ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE
RU2014108885A (ru) Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
CN1240382C (zh) 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合
JP2021107447A5 (enExample)
JP5976923B2 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
CN101466387A (zh) 镓(ⅲ)络合物在黑素瘤治疗中的应用
JP2018104290A (ja) ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN1302777C (zh) 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060208

Termination date: 20100426